Evidence map›Paper›PMID 40558871›Full record

ArticleJournal of xenobiotics2025

The Occurrence of Illicit Smart Drugs or Nootropics in Europe and Australia and Their Associated Dangers: Results from a Market Surveillance Study by 12 Official Medicines Control Laboratories.

Celine Vanhee, Eric Deconinck, Mark George, Andrew Hansen, Andreas Hackl, Uwe Wollein, Oliver El-Atma, Nico Beerbaum, Federica Aureli, Anna Borioni and 9 more

Abstract read
In one paragraph

Article in Journal of xenobiotics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Celine VanheeScientific Direction Chemical and Physical Health Risks, Service of Medicines and Health Products, Sciensano, J. Wytsmanstraat 14, 1050 Brussels, Belgium.ORCID 0000-0002-6634-3706
Eric DeconinckScientific Direction Chemical and Physical Health Risks, Service of Medicines and Health Products, Sciensano, J. Wytsmanstraat 14, 1050 Brussels, Belgium.ORCID 0000-0001-6980-6684
Mark GeorgeTherapeutic Goods Administration Laboratories, Australian Government Department of Health and Aged Care, P.O. Box 100, Woden, ACT 2606, Australia.
Andrew HansenTherapeutic Goods Administration Laboratories, Australian Government Department of Health and Aged Care, P.O. Box 100, Woden, ACT 2606, Australia.
Andreas HacklAGES-Österreichische Agentur für Gesundheit und Ernährungssicherheit GmbH, Spargelfeldstraße 191, A-1220 Wien, Austria.
Uwe WolleinDepartment of Pharmacy (OMCL), Bavarian Health and Food Safety Authority LGL-Bayern, Veterinärstraße 2, 85764 Oberschleißheim, Germany.ORCID 0000-0002-0383-409X
Oliver El-AtmaState Institute of Chemical and Veterinary Analysis Karlsruhe, Weißenburger Str. 3, 76187 Karlsruhe, Germany.
Nico BeerbaumDepartment Lebensmittel und Arzneimittel, Landeslabor Berlin-Brandenburg-Institut für Lebensmittel, Arzneimittel, Tierseuchen und Umwelt, Rudower Chaussee 39, 12489 Berlin, Germany.
Federica AureliNazionale Controllo e Valutazione dei Farmaci Reparto Farmaci Chimici, Direttore, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Roma, Italy.
Anna BorioniNazionale Controllo e Valutazione dei Farmaci Reparto Farmaci Chimici, Direttore, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Roma, Italy.ORCID 0000-0003-4593-9460
Magdalena PoplawskaNational Medicines Institute, 30/34 Chelmska Str., 00-725 Warsaw, Poland.
Agata BlazewiczNational Medicines Institute, 30/34 Chelmska Str., 00-725 Warsaw, Poland.
Karin RoschelLaboratoire National de Santé, Rue Louis Rech 1, L-3555 Luxembourg, Luxembourg.
Claude MarsonLaboratoire National de Santé, Rue Louis Rech 1, L-3555 Luxembourg, Luxembourg.
Magnolia Mendoza BarriosChemical and Pharmaceutical Division, Medicines for Human Use Department, Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Calle Campezo 1, Edificio 8, E-28022 Madrid, Spain.
Birgit HakkarainenSwedish Medical Products Agency, Box 26, Dag Hammarskjölds väg 42, SE-751 03 Uppsala, Sweden.
Andreas BlomgrenSwedish Medical Products Agency, Box 26, Dag Hammarskjölds väg 42, SE-751 03 Uppsala, Sweden.
Ingrid Bakker-'t HartNational Institute for Public Health and the Environment, P.O. Box 1, 3721 MA Bilthoven, The Netherlands.
Marta MiquelThe European Directorate for the Quality of Medicines & HealthCare, Council of Europe, 7 allée Kastner, CS 30026, F-67081 Strasbourg, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, an increasing number of case reports have mentioned the presence of illicit nootropics, smart drugs or mind doping products on the market. To better understand the extent of the problem, a market surveillance study was organised by the General European Official Medicines Control Laboratory Network and associated member Australia to detect substandard, falsified or illegal medicines or dietary supplements containing unauthorised nootropic molecules of natural or synthetic origin. From January 2020 to September 2024, 159 different samples were documented, which yielded a comprehensive dataset of 166 molecular identification entries. Within this dataset, 34 distinct molecules were identified. Most samples were sold or presented as dietary supplements (49%) or medicines (32%). The vast majority (69%) were collected from the illegal market. Prescription drugs and non-authorised drugs only available on prescription in Russia were found in pharmacological quantities; some of the latter (noopept, phenylpiracetam and phenibut) were intercepted as large bulk quantities of raw material. Unauthorised novel foods, prescription or higher amounts of melatonin, and clinically uncharacterised research molecules were also reported. This study highlights the need for more active monitoring and screening of such products, as consumption of some of the reported samples could have detrimental health effects. Furthermore, as a large number of the samples were presented as dietary supplements, consumers may not be aware of the possible dangers and side-effects of these products.

Indexed as

illegal medicinal productsmedicines in disguisenootropic drugsresearch chemicalunauthorised novel food

Identifiers

PMID40558871
PMCPMC12193813

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.